Project Grant R35CA304457
Award Date 8/18/25
Completion Date 7/31/32
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This $495,715 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The research aims to develop faithful preclinical models to study the progression from familial platelet disorders to full-blown AML, and to identify critical molecular dependencies such as...
- This federal Project Grant award of $402,600, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 snRNP complex for the treatment of acute myeloid leukemia (AML). The Sloan-Kettering Institute for Cancer Research, a leading nonprofit cancer research organization, is the awardee for this 5-year project, which commenced on April 3, 2025. The goal is to advance these...
- This federal Project Grant award for $730,398 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the Sloan-Kettering Institute for Cancer Research to investigate the relationship between leptomeningeal cancer cell growth and the inflammatory signaling molecule CXCL1 in the leptomeningeal space surrounding the brain and spinal cord. The goal is to mechanistically dissect the CXCL1-CXCR2 signaling axis and interrupt cancer cell responses to this...
- This federal Project Grant award of $458,698.00, awarded on March 10, 2025 by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports comprehensive research to understand the fundamental biological mechanisms underlying acute myeloid leukemia (AML) development, progression, and potential interventions. The research, to be conducted by the Regents of the University of Michigan, aims to identify cellular and molecular mechanisms that enable the persistence and regrowth of...
- This $530,106 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Biology Research federal grant program (CFDA 93.396). The grant aims to target and mechanistically interrogate polyamine metabolism in leukemia stem cells (LSCs) with the long-term objective of developing LSC-directed therapy to improve outcomes for patients with acute myeloid leukemia (AML). The award was made to Childrens Hospital Medical Center in Cincinnati, Ohio, a prominent non-profit...
- The Sloan-Kettering Institute for Cancer Research was awarded a $736,168 Project Grant by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) on August 1, 2025. The grant supports the development of novel antibody-drug conjugates (ADCs) that can deliver potent radiosensitizing payloads to antigen-bearing tumor cells, with the goal of improving the therapeutic index of radiotherapy. Key aspects of the research include: Creating first-in-class ADCs with DNA damage response...
- This Project Grant award of $292,028 from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) federal grant program, supports research conducted by the Sloan-Kettering Institute for Cancer Research in New York. The goal of the 5-year project is to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer cell clones. The research will employ single-cell whole-genome sequencing,...
- The National Cancer Institute (NCI) awarded a $716,521 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research in New York. The 5-year grant, awarded on August 25, 2025, supports the development and evaluation of DLL3-targeted, IL18-secreting chimeric antigen receptor (CAR) T cells for the treatment of small cell lung cancer (SCLC). The research aims to determine the safety and preliminary efficacy of this novel immunotherapy...
- The Sloan-Kettering Institute for Cancer Research was awarded a $205,700 Project Grant by the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), to conduct research on targeting chromosomal instability in the evolution of resistance to matched therapies against colorectal cancer. The research aims to understand how intrinsic tumor features enable increased chromosomal instability, leading to rapid resistance to targeted cancer therapies. The project...
- This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...